Sutro Biopharma Income Statement (2016-2025) | STRO

Income Statement Dec2016 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
14.66M28.05M8.52M10.65M5.90M28.10M25.15M8.63M12.67M10.41M16.92M113.72M13.01M17.80M8.52M14.81M5.70M63.74M9.69M6.60M
Operating items
Research & Development (Quarter)
22.56M25.31M26.60M29.93M29.99M32.33M31.71M43.13M39.40M41.59M45.67M53.77M56.88M62.02M62.11M71.04M51.60M38.33M39.85M36.64M
Wages, Salaries and Other (Quarter)
28.40M28.27M28.94M22.30M8.51M3.86M0.57M2.81M
Selling, General & Administrative (Quarter)
11.11M12.54M16.59M15.76M15.04M15.14M14.64M14.72M15.51M15.00M15.27M16.80M12.72M12.37M14.33M9.03M13.27M10.34M8.74M8.66M
Restructuring Costs (Quarter)
4.25M13.01M7.31M1.58M
Other Operating Expenses (Quarter)
16.79M5.42M2.25M2.81M
Operating Expenses (Quarter)
33.67M37.85M43.19M45.69M45.03M47.48M46.36M57.85M54.91M56.59M60.94M70.57M69.60M74.39M76.44M80.07M85.91M67.09M58.15M49.70M
Operating Income (Quarter)
-19.01M-9.80M-34.67M-35.04M-39.13M-19.38M-21.21M-49.22M-42.24M-46.18M-44.01M43.15M-56.59M-48.69M-67.92M-65.26M-68.51M-3.35M-48.46M-38.05M
EBIT (Quarter)
-19.01M-9.80M-34.67M-35.04M-39.13M-19.38M-21.21M-49.22M-42.24M-46.18M-44.01M43.15M-56.59M-48.69M-67.92M-65.26M-68.51M-3.35M-48.46M-38.05M
Non-operating items
Interest & Investment Income (Quarter)
0.20M0.17M0.11M-3.62M-0.66M-0.59M-2.79M2.13M-2.99M-2.92M-2.74M4.56M-2.21M-1.76M4.88M-8.04M3.19M-1.04M2.01M12.32M
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)
-1.62M0.68M19.13M-4.83M-7.45M-8.17M-8.40M-8.79M
Net income details
EBT (Quarter)
-19.67M-6.15M-30.90M-38.12M-39.11M-23.51M-19.49M-34.59M-49.66M-38.37M-47.45M46.87M-58.21M-48.01M-48.79M155.01M-65.33M-11.52M-56.86M-46.84M
Tax Provisions (Quarter)
2.50M0.40M0.15M1.84M15.81M0.01M2.39M-0.02M-0.09M
Profit After Tax (Quarter)
-30.36M-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.07M-58.21M-48.02M-48.79M-72.44M-75.97M-11.50M-56.86M-46.76M
Equity Income (Quarter)
-10.69M4.33M4.48M-2.57M0.56M-3.74M3.50M11.81M-6.99M8.32M0.69M7.89M3.68M4.81M
Income from Continuing Operations (Quarter)
-19.67M-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.07M-58.21M-48.02M-48.79M152.62M-65.33M-11.50M-56.86M-46.76M
Consolidated Net Income (Quarter)
-19.67M-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.07M-58.21M-48.02M-48.79M152.62M-65.33M-11.50M-56.86M-46.76M
Income towards Parent Company (Quarter)
-19.67M-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.07M-58.21M-48.02M-48.79M152.62M-65.33M-11.50M-56.86M-46.76M
Net Income towards Common Stockholders (Quarter)
-19.67M-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.07M-58.21M-48.02M-48.79M152.62M-65.33M-11.50M-56.86M-46.76M
Additional items
EPS (Basic) (Quarter)
-0.66-0.13-0.67-0.83-0.84-0.55-0.37-0.61-0.85-0.64-0.810.52-0.59-0.59-0.59-27.33-0.91-0.14-0.67-20.78
EPS (Weighted Average and Diluted) (Quarter)
-0.13-0.67-0.83-0.84-0.55-0.37-0.61-0.85-0.64-0.810.52-0.59-0.59-0.59-27.33-0.91-0.14-0.67-20.78
Shares Outstanding (Weighted Average) (Quarter)
45.91M46.12M46.06M46.12M46.50M46.96M48.62M50.74M58.72M60.34M59.89M60.16M61.46M81.22M74.93M7.74M83.11M83.85M84.87M8.50M
Shares Outstanding (Diluted Average) (Quarter)
46.12M46.06M46.12M46.50M46.96M52.35M50.74M58.72M60.34M59.89M60.16M61.46M71.34M82.04M7.74M83.11M84.58M84.87M8.50M
EBITDA (Quarter)
-19.01M-9.80M-34.67M-35.04M-39.13M-19.38M-21.21M-49.22M-42.24M-46.18M-44.01M43.15M-56.59M-48.69M-67.92M-65.26M-68.51M-3.35M-48.46M-38.05M
Interest Expenses (Quarter)
0.86M0.85M0.82M0.61M0.66M0.59M2.79M
Shares Outstanding (Quarter)
46.10M46.14M46.26M46.33M46.93M48.67M54.63M57.50M60.16M60.47M60.90M6.15M0.48M81.86M82.40M8.31M84.35M84.72M85.10M8.58M
Tax Rate (Quarter)
-10.63-0.80-0.39-3.8833.72-0.021.540.160.19